ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
British Journal of Cancer: Zurletrectinib Is a Next-Generation TRK Inhibitor With Strong Intracranial Activity Against NTRK Fusion-Positive Tumors With On-Target Resistance to First-generation Agents
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents. -
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
November 29, 2018The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. -
US approves first ever TRK inhibitor
November 28, 2018Bayer and Loxo Oncology’s Vitrakvi has become the first ever TRK inhibitor to be approved in the US, having been cleared to treat advanced solid tumours harbouring an NTRK gene fusion.
Pharma Sources Insight January 2025
